NeuroPace, Inc.
NPCE
Rank in Stocks
#12659
NeuroPace, Inc. operates as a medical device company in the United States. The... NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Share Price
$13.12
Last synced: 2026-11-09
Market Cap
$450.33M
Change (1 day)
4.96%
Change (1 year)
-2.74%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade NeuroPace, Inc. (NPCE)
Category
Healthcare
Operating Margin for NeuroPace, Inc. (NPCE)
Operating Margin as of November 2026 TTM: -15.26%
According to NeuroPace, Inc.'s latest financial reports, its current operating margin (TTM) is -15.26%. At the end of 2025 the company had an operating margin of -16.34%.
Operating Margin history for NeuroPace, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -15.26% | -6.61% |
| 2025 | -16.34% | -39.75% |
| 2024 | -27.12% | -34.71% |
| 2023 | -41.54% | -53.65% |
| 2022 | -89.62% | 70.57% |
| 2021 | -52.54% | 65.64% |
| 2020 | -31.72% | -46.77% |
| 2019 | -59.59% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -101.00% |
US
|
|
| 18.08% | -101.18% |
IE
|
|
| 21.25% | -101.39% |
US
|
|
| 21.05% | -101.38% |
US
|
|
| 28.09% | -101.84% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about NeuroPace, Inc.'s operating margin
What is NeuroPace, Inc.'s operating margin?
NeuroPace, Inc.'s operating margin is -15.26%, as of Nov 2026.
What was NeuroPace, Inc.'s operating margin in 2025?
In 2025, NeuroPace, Inc.'s operating margin was -16.34%, compared with -27.12% in 2024.
How has NeuroPace, Inc.'s operating margin changed since 2020?
From 2020 to 2025, NeuroPace, Inc.'s operating margin was highest in 2025 (-16.34%) and lowest in 2022 (-89.62%).
How does NeuroPace, Inc.'s operating margin compare with similar companies?
NeuroPace, Inc.'s operating margin (-15.26%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.